Sökning: "immune risk"
Visar resultat 1 - 5 av 683 avhandlingar innehållade orden immune risk.
1. The Immune System in the Oldest-Old : Clinical and Immunological Studies in the NONA Immune Cohort
Sammanfattning : The oldest-old (people aged 80 or older) constituted 5 % of the population in Sweden in 2000, an increase from 1.5 % fifty years earlier. The immune system undergoes dramatic changes at high age, sometimes referred to as “immunosenescence”. LÄS MER
2. Methotrexate and Risk of Cutaneous Melanoma
Sammanfattning : Methotrexate (MTX) is an anti-inflammatory and immunosuppressive drug commonly used to treat psoriasis, psoriatic arthritis and rheumatoid arthritis. Cutaneous malignant melanoma (CMM) is a common and dangerous type of skin cancer and in recent decades a noteworthy increase in incidence has been observed. LÄS MER
3. Risk and prognostic factors for malignant glioma
Sammanfattning : Background: Glioblastoma is the most common and aggressive type of glioma and associated with poor prognosis. Apart from ionizing radiation and some rare genetic disorders, few aetiological factors have been identified for primary brain tumours. LÄS MER
4. Effects of Complement Opsonization of HIV on Dendritic Cells : and Implications for the Immune Response
Sammanfattning : Dendritic cells are key players during HIV pathogenesis, and shape both the immediate immune response at the site of infection as well as directing the adaptive immune response against the virus. HIV has developed a plethora of immune evasion mechanisms that hijack dendritic cell functions, suppressing their ability to mount an accurate immune response and exploiting them for efficient viral transfer to target T cells. LÄS MER
5. Immune cell infiltration and prognosis in colorectal cancer
Sammanfattning : Background: Colorectal cancer (CRC) is globally the second most common form of cancer among women, and third in men. It is also one of the most common causes of cancer-related death in high-income countries. Surgical resection is the basis for curative therapy but still almost half of the patients die from metastatic disease. LÄS MER